Australia's most trusted
source of pharma news
Friday, 09 May 2025
Posted 4 December 2023 AM
BMS and MSD are seeking to have their checkpoint inhibitors automatically listed on the PBS for certain cancers at the point of TGA registration.
A proposal to fast-track access to three top-selling drugs will be considered at the PBAC Intracycle meeting on 6 December. It would be the first such agreement in immunotherapy and if successful would mark a seismic shift in the way treatments are reimbursed in Australia.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.